Your browser doesn't support javascript.
loading
Antibiotic-Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy.
Suaifan, Ghadeer A R Y; Abdel Rahman, Diana M A; Abu-Odeh, Ala' M; Abu Jbara, Fahid; Shehadeh, Mayadah B; Darwish, Rula M.
Affiliation
  • Suaifan GARY; Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan.
  • Abdel Rahman DMA; Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan.
  • Abu-Odeh AM; Department of Pharmaceutical Chemistry and Pharmacognosy, School of Pharmacy, Applied Science Private University, Jordan, Amman.
  • Abu Jbara F; School of Medicine, The University of Jordan, Amman, Jordan.
  • Shehadeh MB; Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan.
  • Darwish RM; Department of Pharmaceutics and Pharmaceutical Biotechnology, School of Pharmacy, The University of Jordan, Amman, Jordan.
PLoS One ; 18(3): e0282705, 2023.
Article in En | MEDLINE | ID: mdl-36893145
ABSTRACT
Minimizing antibiotic resistance is a key motivation strategy in designing and developing new and combination therapy. In this study, a combination of the antibiotics (cefixime, levofloxacin and gentamicin) with Lysobacter enzymogenes (L. enzymogenes) bioactive proteases present in the cell- free supernatant (CFS) have been investigated against the Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and the Gram-negative Escherichia coli (E. coli O157H7). Results indicated that L. enzymogenes CFS had maximum proteolytic activity after 11 days of incubation and higher growth inhibitory properties against MSSA and MRSA compared to E. coli (O157H7). The combination of L. enzymogenes CFS with cefixime, gentamicin and levofloxacin at sub-MIC levels, has potentiated their bacterial inhibition capacity. Interestingly, combining cefixime with L. enzymogenes CFS restored its antibacterial activity against MRSA. The MTT assay revealed that L. enzymogenes CFS has no significant reduction in human normal skin fibroblast (CCD-1064SK) cell viability. In conclusion, L. enzymogenes bioactive proteases are natural potentiators for antimicrobials with different bacterial targets including cefixime, gentamicin and levofloxacin representing the beginning of a modern and efficient era in the battle against multidrug-resistant pathogens.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Methicillin-Resistant Staphylococcus aureus Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Document type: Article Affiliation country: Jordan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Methicillin-Resistant Staphylococcus aureus Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2023 Document type: Article Affiliation country: Jordan